Novel Alzheimer’s Drug Targeting Tau Shows Promise in Mid-Stage Trial

(MedPage Today) — The tau-targeting agent diranersen did not meet the primary endpoint of the phase II CELIA trial, but that isn't stopping the drug from moving forward. The placebo-controlled study is the first to show a cognitive benefit and…

Source: MedPage Today — Headlines